AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 287: H2364-H2366, 2004. First published June 10, 2004; doi:10.1152/ajpheart.00416.2004
0363-6135/04 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/5/H2364    most recent
00416.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Vondriska, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Vondriska, T. M.

REPORT

Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in pharmacological cardioprotection

Jun Zhang,1 Peipei Ping,1 Guang-Wu Wang,1 Ming Lu,1 Dawn Pantaleon,1 Xian-Liang Tang,2 Roberto Bolli,2 and Thomas M. Vondriska1

1Departments of Physiology and Medicine/Cardiology, Cardiovascular Research Laboratories, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095; and 2Division of Cardiology, University of Louisville, Louisville, Kentucky 40292

Submitted 10 May 2004 ; accepted in final form 1 June 2004


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS AND DISCUSSION
 GRANTS
 REFERENCES
 
Previous studies have indicated that PKC-{epsilon} is a central regulator of protective signal transduction in the heart. However, the signaling modules through which PKC-{epsilon} exerts its protective effects have only begun to be understood. We have identified a novel participant in the PKC-{epsilon} signaling system in cardioprotection, the nonreceptor tyrosine kinase Bmx. Functional proteomic analyses of PKC-{epsilon} signaling complexes identified Bmx as a member of these complexes. Subsequent studies in rabbits have indicated that Bmx is activated by nitric oxide (NO) in the heart, concomitant with the late phase of NO donor-induced protection, and provide the first analysis of Bmx expression/distribution in the setting of cardioprotection. In addition, increased expression of Bmx induced by NO donors was blocked by the same mechanism that blocked cardioprotection: inhibition of PKC with chelerythrine. These findings indicate that a novel type of PKC-tyrosine kinase module (involving Bmx) is formed in the heart and may be involved in pharmacological cardioprotection by NO donors.

myocardial ischemia; preconditioning; signaling complex; signaling module; nitric oxide


A CRITICAL ROLE for tyrosine kinase signaling during cardioprotection has been demonstrated by multiple laboratories (1, 4, 6, 11, 14, 15). Several studies have implicated the Src family of nonreceptor tyrosine kinases (6, 11, 15); however, many investigations have relied on pharmacological agents to demonstrate a role for these signaling elements. Thus the molecular identity of the specific nonreceptor tyrosine kinases involved in cardioprotection has remained elusive.

Proteomic analysis of myocardial PKC-{epsilon} complexes identified bone marrow tyrosine kinase gene in chromosome X (Bmx, also known as Etk), a member of the Tec/Btk family of nonreceptor tyrosine kinases, as a member of the PKC-{epsilon} subproteome (10). Previous studies have implicated a role for the Tec family in proliferative and senescent cellular processes and, in particular, in mediation of signal transduction by cytokines, growth factors, and G protein-coupled receptors (8, 12). Although one study documented expression of Bmx in the endocardium and the macrovascular endothelium (3), virtually nothing is known regarding the functional signaling role(s) of Bmx in the heart. Specifically, it is completely unknown 1) whether Bmx is activated by nitric oxide (NO) in the myocardium; 2) whether other nonreceptor tyrosine kinases, such as Bmx, form modules with PKC-{epsilon} in the heart; and 3) whether Bmx participates in cardioprotective signaling. To answer these questions, the expression and activation of Bmx were examined in a well-characterized rabbit model of NO donor-induced late preconditioning. The data indicate that Bmx was activated during protection and was resident in the PKC-{epsilon} complex, suggesting that this molecule may form a novel tyrosine kinase module with PKC-{epsilon}. Given the known cardioprotective role of NO, these data have important implications regarding the ability of this ubiquitous signaling molecule to activate Tec kinases in the heart. Furthermore, the findings suggest a broader role for PKC-nonreceptor tyrosine kinase modules in the myocardium, which includes members outside the Src family.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS AND DISCUSSION
 GRANTS
 REFERENCES
 
This study was performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 86-23).

Conscious rabbit model of diethylenetriamine-NO-induced late cardioprotection. A well-established conscious rabbit model of NO-induced cardioprotection was used as previously described (9, 15). Briefly, male New Zealand White rabbits (2.0–2.5 kg, 3–4 mo of age) were intravenously administered the NO donor diethylenetriamine (DETA)/NO (0.1 mg/kg once every 25 min for 75 min; total dose of 0.4 mg/kg). This dose of DETA/NO has been shown to activate PKC-{epsilon} and to induce a late phase of cardioprotection against infarction and stunning 24 h later (9, 15). The PKC inhibitor chelerythrine (CHE; 5 mg/kg) was given 5 min before the first DETA/NO injection; this CHE dose has been shown to abolish NO-induced activation of PKC-{epsilon} and cardioprotection (9, 15). Hearts were harvested either 30 min or 24 h after the last DETA/NO injection and and stored at –80°C until biochemical analyses were conducted.

Immunoprecipitation and Western blot analysis. Myocardial lysates were fractionated by differential centrifugation. Immunoprecipitation, SDS-PAGE, and immunoblotting were performed as previously described (9, 11, 15). Antibodies to PKC-{epsilon} and Bmx and horseradish peroxidase-conjugated secondary antibodies were obtained from BD Transduction Laboratories. Values are means ± SE. Groups were compared using Student's t-test for unpaired data. P < 0.05 was considered significant.


    RESULTS AND DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS AND DISCUSSION
 GRANTS
 REFERENCES
 
Although previous investigations implicated a role for tyrosine kinases in PKC signaling during cardioprotection (1, 11, 14, 15), characterization of the specific molecules involved is lacking. Several studies have demonstrated a role for Src family tyrosine kinases in cardioprotection (6, 11, 15), but the importance of other nonreceptor tyrosine kinases is less well understood. In the present study, the nonreceptor tyrosine kinase Bmx was found to participate in PKC-{epsilon} signaling in a rabbit model of NO-induced cardioprotection. Taken with our previous study using a transgenic model of cardioprotection in the mouse (10), this finding suggests that a cardioprotective role for Bmx may transcend model and species.

The present investigation demonstrates for the first time that exogenous NO donors activate Bmx in the myocardium, as evidenced by recruitment of Bmx to the particulate fraction. Importantly, the NO donor activated and increased the expression of Bmx concomitant with the late phase of cardioprotection afforded by the drug. Furthermore, the NO donor induced increased expression of Bmx via a PKC-dependent mechanism. These data suggest that a novel class of tyrosine kinases may form modules with PKC-{epsilon} during cardioprotection.

Translocation of Bmx is known to be indicative of activation, and association of Bmx with the membrane has been shown to occur through its lipid-binding plekstrin-homology domain (8, 12). To determine whether Bmx participates in protective signaling systems of the heart, the subcellular distribution of this kinase was examined in the normal heart and after treatment with cardioprotective doses of the NO donor DETA/NO. Under basal conditions, the vast majority (90 ± 9%; Fig. 1B) of Bmx resided in the cytosol of the rabbit heart, in agreement with previous findings in other cell types (8, 12). No translocation of Bmx was observed 30 min after administration of the NO donor (i.e., during the "trigger phase" of NO-induced protection), akin to what was observed for Src tyrosine kinase at this time (15). In contrast to Src, however, the NO donor induced a significant increase in total expression of Bmx (128 ± 2% of control; Fig. 1A), concomitant with redistribution of Bmx to the particulate fraction 24 h later (38 ± 3% in DETA/NO group vs. 10 ± 1% in control group, P > 0.05; Fig. 1B). This finding is particularly interesting, because translocation of Bmx, indicative of its activation (12), occurred at the time at which the heart was protected against ischemic insult: 24 h after NO donor administration (i.e., during the "mediator phase" of NO-induced protection).



View larger version (37K):
[in this window]
[in a new window]
 
Fig. 1. Bmx participates in nitric oxide (NO) donor-induced cardioprotection in the rabbit. A: NO donors induce increased Bmx expression via a PKC-dependent mechanism. At 24 h after NO donor [diethylenetriamine (DETA)/NO] administration, expression of Bmx was detected by Western immunoblotting (IB). Pretreatment with the PKC inhibitor chelerythrine (CHE) blocked increased expression of Bmx. B: NO donors induce translocation of Bmx at 24 h but not at 30 min. Cardiac tissues were fractionated at 30 min and 24 h after NO donor treatment and subjected to Western immunoblotting for Bmx. NO donor-induced translocation was observed at 24 h and was insensitive to PKC inhibition with CHE. *P < 0.05 vs. control. #P = not significant vs. DETA/NO. Values are means ± SE. C: Bmx associates with PKC-{epsilon} in the particulate, but not the cytosolic, fraction. Cardiac tissues were fractionated, PKC-{epsilon} complexes were isolated by immunoprecipitation (IP), and Bmx was detected by immunoblotting (no interaction of Bmx with IgG was observed; data not shown). n = 4 in all experiments.

 
To examine whether activation of Bmx by NO in the heart was dependent on PKC, rabbits were pretreated with the PKC inhibitor CHE before they were preconditioned with the NO donor. Inhibition of PKC with CHE, at a dose previously shown to block the cardioprotective effects of ischemia- and NO-induced preconditioning (9) and, more recently, sildenafil-induced protection (2), blocked the increased expression (Fig. 1A), but not translocation (Fig. 1B), of Bmx observed in response to NO donor treatment. These data suggest that NO-induced Bmx expression and translocation are controlled by distinct mechanisms and that only the former is PKC dependent. In confirmation of our previous proteomic studies of PKC-{epsilon}-mediated cardioprotection in the mouse, Bmx was found to localize to PKC-{epsilon} complexes (as detected by immunoprecipitation for PKC-{epsilon} followed by immunoblotting for Bmx) in the particulate, but not the cytosolic, fraction of the rabbit myocardium (Fig. 1C).

It is important to note that although the {epsilon}-isoform of PKC has been shown to be protective in the mouse, studies from other species have implicated different isoforms of PKC in cardioprotection, for example, the {alpha}-isoform in dogs (7) and pigs (13) and the {delta}-isoform in some forms of protection in rats (5). Indeed, the species dependence of PKC isoform-specific signaling to Bmx and other Tec family kinases in the myocardium will be a key issue to resolve in future studies. At this point, the downstream tasks regulated by Bmx in cardioprotection are completely unknown. Previous studies have shown that Bmx activates STAT and NF-{kappa}B in noncardiac cells (8, 12). Therefore, these transcription factors, both of which have been shown to be necessary for cardioprotection, may be modulated by Bmx-dependent mechanisms in the heart. Furthermore, cross talk between Src and Bmx pathways and the role of Src in activation of Bmx [which has been documented in noncardiac cells (8, 12)] remain to be determined in the setting of cardioprotection.

It has not escaped our attention that increased expression of a second, higher-molecular-weight species of Bmx is observed in the protected myocardium at 24 h (Fig. 1A). The possibility exists that this second, higher-molecular-weight band is a posttranslationally modified species of Bmx. This modified species may represent an active, double tyrosine-phosphorylated form of Bmx, which is in agreement with previous investigations suggesting dual tyrosine phosphorylation as a mechanism to activate Tec kinases (8). A second possibility would be a heretofore unrecognized serine/threonine phosphorylation of Bmx (in support of which, Bmx contains 9 putative PKC phosphorylation sites). The potential role of posttranslational modifications of Bmx in cardioprotective signal transduction is the focus of ongoing studies.

The present study is the first, to our knowledge, to report NO-dependent activation of the nonreceptor tyrosine kinase Bmx in the heart and to implicate a role for this kinase in cardioprotection. These findings are potentially important with regard to a greater understanding of PKC-tyrosine kinase modules in the heart.


    GRANTS
 TOP
 ABSTRACT
 METHODS
 RESULTS AND DISCUSSION
 GRANTS
 REFERENCES
 
This study was supported in part by American Heart Association Grant 0110053B (T. M. Vondriska); National Heart, Lung, and Blood Institute Grants HL-43151, HL-55757, and HL-68088 (all to R. Bolli), and HL-63901 and HL-65431 (both to P. Ping); and by the Laubisch Endowment at University of California at Los Angeles.


    ACKNOWLEDGMENTS
 
We thank Dr. Hsing-Jien Kung for helpful suggestions with the Bmx protein.


    FOOTNOTES
 

Address for reprint requests and other correspondence: T. M. Vondriska, Cardiovascular Research Laboratories, Suite 1619 MRL Bldg., 675 Charles E. Young Dr., David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 (E-mail: tvondriska{at}mednet.ucla.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS AND DISCUSSION
 GRANTS
 REFERENCES
 

  1. BainesCP, Wang L, Cohen MV, and Downey JM. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol 30: 383–392, 1998.[CrossRef][ISI][Medline]
  2. DasA, Ockaili R, Salloum F, and Kukreja RC. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 286: H1455–H1460, 2004.[Abstract/Free Full Text]
  3. EkmanN, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, and Alitalo K. Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation 96: 1729–1732, 1997.[Abstract/Free Full Text]
  4. FryerRM, Schultz JE, Hsu AK, and Gross GJ. Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in rat hearts. Am J Physiol Heart Circ Physiol 275: H2009–H2015, 1998.[Abstract/Free Full Text]
  5. FryerRM, Wang Y, Hsu AK, and Gross GJ. Essential activation of PKC-{delta} in opioid-initiated cardioprotection. Am J Physiol Heart Circ Physiol 280: H1346–H1353, 2001.[Abstract/Free Full Text]
  6. HatorriR, Otani H, Uchiyama T, Imamura H, Cui J, Maulik N, Cordis GA, Zhu L, and Das DK. Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning. Am J Physiol Heart Circ Physiol 281: H1066–H1074, 2001.[Abstract/Free Full Text]
  7. KitakazeM, Funaya H, Minamino T, Node K, Sato H, Ueda Y, Okuyama Y, Kuzuya T, Hori M, and Yoshida K. Role of protein kinase C-{alpha} in activation of ecto-5'-nucleotidase in the preconditioned canine myocardium. Biochem Biophys Res Commun 239: 171–175, 1997.[CrossRef][ISI][Medline]
  8. ManoH. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev 10: 267–280, 1999.[CrossRef][ISI][Medline]
  9. PingP, Takano H, Zhang J, Tang XL, Qiu Y, Li RC, Banerjee S, Dawn B, Balafanova Z, and Bolli R. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ Res 84: 587–604, 1999.[Abstract/Free Full Text]
  10. PingP, Zhang J, Pierce WM, and Bolli R. Functional proteomic analysis of PKC{epsilon} signaling complexes in the normal heart and during cardioprotection. Circ Res 88: 59–62, 2001.[Abstract/Free Full Text]
  11. PingP, Zhang J, Zheng YT, Li RC, Dawn B, Tang XL, Takano H, Balafanova Z, and Bolli R. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ Res 85: 542–550, 1991.
  12. QiuY and Kung HJ. Signaling network of the Btk family kinases. Oncogene 19: 5651–5661, 2000.[CrossRef][ISI][Medline]
  13. SchulzR, Gres P, Skyschally A, Duschin A, Belosjorow S, Konietzka I, and Heusch G. Ischemic preconditioning preserves connexin 43 phosphorylation during sustained ischemia in pig hearts in vivo. FASEB J 17:1355–1357, 2003.[Abstract/Free Full Text]
  14. VahlhausC, Schulz R, Post H, Rose J, and Heusch G. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol 30: 197–209, 1998.[CrossRef][ISI][Medline]
  15. VondriskaTM, Zhang J, Song C, Tang XL, Cao X, Baines CP, Pass JM, Wang S, Bolli R, and Ping P. PKC{epsilon}-Src modules direct signal transduction in nitric oxide-induced cardioprotection: complex formation as a means for cardioprotective signaling. Circ Res 88: 1306–1313, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Cancer Res.Home page
T. Tu, D. Thotala, L. Geng, D. E. Hallahan, and C. D. Willey
Bone Marrow X Kinase-Mediated Signal Transduction in Irradiated Vascular Endothelium
Cancer Res., April 15, 2008; 68(8): 2861 - 2869.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. H. Chau, C. A. Clavijo, H.-T. Deng, Q. Zhang, K.-J. Kim, Y. Qiu, A. D. Le, and D. K. Ann
Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems
Am J Physiol Cell Physiol, August 1, 2005; 289(2): C444 - C454.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. Mathur, S. Kaga, L. Zhan, D. K. Das, and N. Maulik
Potential candidates for ischemic preconditioning-associated vascular growth pathways revealed by antibody array
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H3006 - H3010.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/5/H2364    most recent
00416.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Vondriska, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Vondriska, T. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.